Тэги:
#Speaker:_Farhad_Ravandi #Event:_ASH_2017 #Format:_Interview #Subject:_Acute_Myeloid_Leukemia #Subject:_Leukemia #Medicines:_Decitabine #Field:_Treatment #NCT01786343 #response_rate #clinical_trials #toxicity #outcomes #randomized #monotherapy #Phase_II #safety #efficacy #dosing #dosing_schedule #chemotherapy #elderly #elderly_patientsКомментарии: